国产久免费热视频在线,青青视频97

ASCO 2025: 14 Chinese ADC Therapies Showcase Strong Efficacy Across Multiple Tumors ASCO At ASCO 2025, 14 Chinese ADC therapies demonstrated impressive efficacy and safety across various cancers, including breast, lung, gastric, and urothelial, signaling strong global potential for domestically developed treatments.
IBI-363 Shines at ASCO 2025: Innovent’s Breakthrough Immunotherapy Shows Game-Changing Results ASCO Discover how Innovent's IBI-363 made a groundbreaking impact at ASCO 2025 with impressive efficacy in NSCLC, melanoma, and colorectal cancer. A potential game-changer in next-gen immunotherapy.
ASCO 2025 Colorectal Cancer Highlights: Plenary & Oral Sessions, Breakthrough Treatments & Studies ASCO Discover the latest breakthroughs in colorectal cancer at ASCO 2025, featuring key plenary and oral presentations on innovative treatments like ATOMIC, BREAKWATER, ANCHOR, and KRAS G12C inhibitors. Stay ahead in oncology research.
Trump's Pharma Tariffs & Pricing Reforms: S&P Warns of Generic Sector Risks Trump S&P Global reports that major pharma companies can withstand Trump’s proposed drug tariffs and MFN pricing, but warns that generic manufacturers may face serious risks from cost pressures and supply chain disruptions.
Pharmaceutical Export and Import Report (Jan-Apr 2025) Market Trend China's Western medicine trade saw stable performance from Jan–Apr 2025, with exports rising 4.0% and imports down 3.4%. However, API exports to the U.S. dropped sharply in April, reflecting tariff impacts and shifting market dynamics.
2025 ASCO: Major Breakthroughs in Gastric Cancer Treatment: Latest Advances Preview ASCO Discover the latest breakthroughs in gastric cancer treatment from the 2025 ASCO Annual Meeting, including immunotherapy, targeted therapies, and CAR-T advances improving survival and hope for patients worldwide.
ASCO 2025: Postoperative ctDNA in Pancreatic & Oral Cancer, Desmoid Tumor Therapy ASCO Postoperative ctDNA-based MRD predicts recurrence in pancreatic and oral cancers, guiding personalized therapy. Radiotherapy plus bevacizumab shows efficacy in desmoid tumors with ATR mutation as a key predictor.
2025 ASCO: Domestic ADCs, Bispecifics, Trispecifics, Small Molecules ASCO Explore the major highlights from ASCO 2025, featuring cutting-edge Chinese innovations in ADCs, bispecific and trispecific antibodies, and small molecule drugs with promising clinical trial results across multiple cancer types.
ASCO 2025: Latest Clinical Advances in Solid Tumor CAR-T Therapies from China and the U.S. ASCO Explore key updates from ASCO 2025 on solid tumor CAR-T therapies, including clinical trial data from leading Chinese firms and U.S. companies like A2 Bio, showcasing promising safety and efficacy results.
ASCO 2025: Breakthrough Cancer Trials, Innovative Therapies, and China's Rising Role ASCO The 2025 ASCO meeting highlights breakthrough cancer trials, including advances in breast and blood cancers, innovative bispecific antibodies, radiopharmaceuticals, and China’s growing influence in oncology innovation.

< Pre 1...16 17 181920 21 22...26 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

国产91视频久久,亚洲综合色图在线观看,五月天操逼网,日韩色色AV,青青在线A片,亚洲最大色在线观看,欧美熟妇丝袜诱惑,青青操逼视频,日韩无码操出水